InNexus Biotechnology Inc.

From Wikipedia, the free encyclopedia

This article or section is written like an advertisement.
Please help rewrite this article from a neutral point of view.
Mark blatant advertising which would require a fundamental rewrite in order to become encyclopedic for speedy deletion, using {{db-spam}}. (May 2008)

This article is orphaned as few or no other articles link to it.
Please help introduce links in articles on related topics. (May 2008)

InNexus Biotechnology Inc.
Type	Public (TSX:IXS)
Founded	2001, British Columbia, Canada
Headquarters	Principal Management in Scottsdale, Arizona, United States
Key people	Jeff Morhet, Chairman and CEO Wade Brooksby, CFO Gilbert R. Gabo, Esq., Vice President of Operations and Director of Legal Affairs Thomas Kindt, Chief Scientific Officer
Industry	Biotechnology
Products	DXL625 (CD20) for prospective treatment of Non-Hodgkin’s Lymphoma, preclinical stage, DXL702 (HER2/neu) for prospective treatment of breast cancer, preclinical stage. DXLdiagnostics DXLmouse
Employees	30 (2008)
Website	http://www.ixsbio.com

InNexus Biotechnology, Inc. is a drug company based in British Columbia, Canada, with principal management located in the Mayo Clinic MCCRB Building on the Mayo Clinic Campus in Scottsdale, Arizona, USA. InNexus is currently developing monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology for both therapeutic and diagnostic applications. InNexus was founded in 2001 and became a publicly traded corporation in 2003 on the Toronto Stock Exchange (TSX: IXS).

InNexus is currently developing what is referred to as DXL-modified antibodies, wherein certain autophilic peptides are integrated with a monoclonal antibody. The DXL-modified antibodies have been shown to have enhanced binding affinity and, as a result, greater potency for use as an improved therapeutic to fight cancer and higher signal strength for use as an improved diagnostic for detecting cancer versus the parent or unmodified antibody.

In May 2008, InNexus announced its novel internship program to begin June 2008 called LABApprentice. Interested applicants and internet viewers will have the opportunity to watch activities of the participants in the eight week program which will culminate in one apprentice being chosen as a new InNexus Biotechnology employee. For more information, go to labapprentice.com[1].